Answers are grounded in this paper and cite their sources.
CAR-T immunotherapy, based on the genetic modification of T lymphocytes that contain a chimeric antigen receptor (CAR), has been a major breakthrough in the treatment of cancer patients since the 2017 approval of Kymriah™ (tisagenlecleucel) by the United States Food and Drug Administration (FDA). To date, six CAR-T cell therapies have been approved by the FDA, showing efficacy in patients with B-cell cancers and multiple myeloma. However, adverse events, such as cytokine release syndrome and neurotoxicity, present serious challenges to successful CAR-T cell therapy. The severity of adverse events correlates with the degree of tumor burden before treatment. This observation is supported by the use of CD19-specific CAR-T cells in autoimmune diseases such as systemic lupus erythematosus and anti-synthetase syndrome. These results indicate that early initiation of CAR-T cell therapy with a low tumor burden, or the use of a tumor-shrinking strategy prior to CAR-T cell infusion, may reduce the severity of adverse events. CAR-T cell therapy is expensive and has limited efficacy in solid tumors. Research is currently under way to increase the effectiveness of CAR-T therapy in patients with solid tumors not responding to conventional treatment.
No takes yet. Share an insight, caveat, or question.
Bogacz et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: